IKBKE and neoplasm: In addition to its role in inhibiting JAK/STAT signaling, preclinical studies demonstrated the efficacy of CYT387 in triple-negative breast cancer, where it suppressed tumor growth by inhibiting IKBKE-induced NF-κB and STAT activation (29).